Effects of Eculizumab Injection on Plasma MASP-3 and MAp44 Levels,Cardiac Function,Inflammatory Markers,and Myocardial Injury Markers in Patients with Heart Failure
LI Heyun
SONG Chenyan
WANG Yuanyuan
Abstract：Objective To evaluate the effects of eculizumab injection on plasma levels of mannan-binding lectin-associated serine protease 3(MASP-3)and mannan-binding lectin-associated protein 44(MAp44),cardiac function,inflammatory markers,and myocardial injury markers in patients with heart failure,and to explore its therapeutic mechanism and clinical application prospects.Methods A total of 100 patients with heart failure admitted to Zhangjiakou First Hospital between January 2022 and March 2024 were prospectively enrolled and divided into an observation group and a control group,with 50 patients in each group.The control group was administered conventional medication,while the observation group received eculizumab injection on the basis of the same conventional treatment regimen as the control group.Plasma MASP-3 and MAp44 levels were measured before treatment,after 6 weeks of treatment,and after 12 weeks of treatment.Cardiac function(including echocardiographic and electrocardiographic parameters),inflammatory markers[C-reactive protein(CRP),interleukin-6(IL-6)],and myocardial injury markers[cardiac troponin I(cTnI),brain natriuretic peptide(BNP)]were assessed at the same time points.Results After 6 and 12 weeks of treatment,plasma levels of MASP-3 and MAp44 in the observation group were significantly lower than those before treatment(P<0.05).Left ventricular ejection fraction was significantly higher than before treatment(P<0.05),while left ventricular end-diastolic diameter and left ventricular end-systolic diameter were significantly lower(P<0.05).Levels of CRP,IL-6,cTnI,and BNP were also significantly lower than before treatment(P<0.05).After treatment,all the above indicators in the observation group were significantly better than those in the control group(P<0.05).Conclusion The eculizumab injection can effectively regulate the complement system,reduce plasma MASP-3 and MAp44 levels,improve cardiac function,and alleviate myocardial inflammatory injury.It provides a new approach for the treatment of heart failure.Further studies are needed to investigate its specific molecular mechanisms and long-term efficacy.
Keywords：heart failurecomplement modulatormannan-binding lectin-associated serine protease 3mannan-binding lectin-associated protein 44
Publication Date：2026-03-20
Online Publishing Date：2026-03-26(First online date of this platform, not the publication date of the document)
Pages：5( 501-505 )